Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The company plans to add 1700 beds by FY27 through the organic route
International Business is expected to register double-digit growth in constant currency terms
New leadership team announced at NATHEALTH Annual General Meeting 2024
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
This acquisition enables MTD to open new, strategic markets
The company has now received 100% of the incentive owed to the company for the financial year 2022-23 under the PLI scheme
Subscribe To Our Newsletter & Stay Updated